Use of Mifepristone in a Hypercortisolemic Patient With End-Stage Renal Disease on Hemodialysis
Albert W. Coo, MD, FACE; Rebecca Ray, FNP-C • 2021 •
© 2024 Corcept Therapeutics, Incorporated
GRADIENT: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of a Selective Glucocorticoid Receptor Modulator, Relacorilant, in Patients With Autonomous Cortisol Secretion Due to Cortisol-Secreting Adrenal Adenoma(s)/Hyperplasia
Auchus et al. • 2020 • J Endocr Soc. Vol 4, Issue Suppl 1 April-May
Hypercortisolism in Newly Diagnosed Type 2 Diabetes: A Prospective Study of 384 Newly Diagnosed Patients
Steffensen et al • 2019 • Horm Metab Res.
Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study
Pivonello et al • 2021 • Front. Endocrinol., 14 July 2021
Efficacy and Safety of the Selective Glucocorticoid Receptor Modulator, Relacorilant (up to 400 mg/day), in Patients With Endogenous Hypercortisolism
Pivonello et al. • 2019 • American Association of Clinical Endocrinologists (AACE) 28th Annual Scientific & Clinical Congress
Natural History of Adrenal Incidentalomas With and Without Mild Autonomous Cortisol Excess: A Systematic Review and Meta-analysis
Elhassan et al • 2019 • Ann Intern Med.
Evaluation of evidence of adrenal insufficiency in trials of normocortisolemic patients treated with mifepristone.
Yuen et al. • 2017 • J Endocr Soc. 2017;1(4):237-246.
U500 Insulin Screening of Diabetic Patients Uncovers a Large Amount of Undiagnosed Hypercortisolism Consistent With Cushing’s Syndrome
Editorial Team • 2017 • Diabetes
Mifepristone improves octreotide efficacy in resistant ectopic Cushing’s syndrome.
Moraitis AG, Auchus RJ. • 2016 • Case Rep Endocrinol. 2016;2016:8453801.
Prevalence of hypercortisolism in type 2 diabetes patients: a systematic review and meta-analysis
Steffensen et al • 2016 • European Journal of Endocrinology